Lexarias' DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound

Stock Information for Lexaria Bioscience Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lexaria Bioscience Corp.

Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule
Lexaria Attending BIO International Convention
Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company
Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock
Lexaria Announces $2 Million Registered Direct Offering of Common Stock
Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology
Lexaria Updates its Ongoing Human Study GLP-1-H24-4
Lexaria's Human GLP-1 Study #5 Begins Dosing

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.